The Claim
Late-onset myasthenia gravis is not significantly associated with epigenetic aging clocks as measured by DNA methylation patterns, indicating that biological aging quantified by these clocks is not a primary driver of this disease subtype.
What the research says
Not yet evaluated
We are still looking at what the research says.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people who develop myasthenia gravis later in life, DNA methylation patterns that estimate biological age do not show a meaningful link to the disease, suggesting that accelerated aging measured this way is not a main factor in this form of the condition.
See the scientific wording
Late-onset myasthenia gravis shows no significant association with epigenetic aging clocks, indicating that biological aging as measured by DNA methylation is not a primary driver of this subtype, unlike early-onset disease.
In older people, damage to the nerve-muscle connection causes mitochondria to multiply in an attempt to fix the problem, but these extra mitochondria become faulty and leak harmful molecules that trigger the immune system to attack the nerve-muscle connection, leading to muscle weakness. This happens without any change in the DNA methylation patterns that measure biological aging.
What the research says
1 studyIn older adults who get myasthenia gravis, their biological age measured by DNA methylation isn't faster than healthy people of the same age — unlike in younger patients, where the disease does seem to speed up aging. So, this form of the disease isn't caused by accelerated aging at the DNA level.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.